Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Afatinib (Primary) ; Docetaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 05 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 05 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.